

Index

- 10/90 gap, 141–2, 141(n2)
- AB Hassle v Canada (Minister of National Health and Welfare)* [2002] FCA 421 35–6
- Abbott Pharmaceuticals 161, 161(n80), 163, 184, 184(n47), 184(n48), 184(n49)
- access (*see also* use)
- Access to Knowledge, movement 15, 15(n42), 143, 143(n7),
 - Access to Medicines Campaign (*see* access: Campaign for Access to Essential Medicines)
 - benefits of scientific research 1, 2, 25(n22), 59–60, 63–4, 95, 123–4, 173, 175
 - Campaign for Access to Essential Medicines 141
 - education 9, 15(n42)
 - equality 47, 62, 69–70 (*see also* equality)
 - genetic resources (*see* genetic resources)
 - health care and treatment 7, 8(n12), 9, 42, 45–6, 46(n14), 47–9, 50–51, 53–4, 54(n53), 56–7, 59, 61, 69–70, 71–2, 79–81, 84, 112, 112(n42), 135, 141, 144–5, 156, 158, 174, 182, 191 (*see also* primary health care)
 - information 11, 15(n42), 24, 44, 47–50, 54, 56, 59, 69–70, 80, 113, 121, 122–3, 172, 174, 175, 185–7 (*see also* INN; labelling)
 - knowledge and 14–15, 15(n42), 16–17, 67, 171, 172
 - market 8, 25, 32(n55), 80, 84(n21), 88–90, 95, 143, 146, 157, 175–6, 178–9, 189–90
 - medicines 6–10, 12, 14, 14(n37), 17, 20(n11), 21–3, 25, 28, 47, 47(n23), 50–52, 53(n52), 56–8, 66–8, 71–2, 81, 88, 92, 120, 141, 143, 147, 149, 150, 155, 156, 158, 161, 163, 172, 178–80, 193
 - public sphere and participation in public sphere (*see* public sphere)
 - seed 23
 - technology 14, 15(n42), 21, 22, 24–5, 28, 34, 58, 63–4, 67, 80, 82, 136, 141–2, 146
 - use (*see* use: access and use)
 - value 16, 22, 25
 - virus samples (*see* avian influenza)
 - WHO Global Strategy 67
- access and benefit sharing 15, 71–4, 74(n53), 75–6, 123, 129, 137, 163–8 (*see also* benefits, medical and scientific; genetic resources)
- Achmat, Zackie 158, 177
- ACT UP 158
- Actavis UK Ltd v Merck & Co. Inc.* [2008] EWCA Civ 444 22(n17)
- Action Group on Erosion, Technology and Concentration (*see* ETC; *see also* RAFI)
- Africa and African region 16, 156, 168 (*see also* South Africa)
- African Charter on Human and Peoples' Rights 45
- Agreement on Trade-Related Aspects of Intellectual Property Rights (*see* WTO: TRIPS)
- agriculture 25, 104(n12), 104(n13), 115(n51), 117 (*see also* genetically-modified crops and agriculture)
- Alma-Ata, Declaration of (*see* World Health Organization (WHO): Declaration of Alma-Ata)
- animals 87, 93(n56), 107(n21), 108, 110, 115(n51)
- commodification and property 13, 104(n12), 115–16,
 - genetic research and transgenic species 97, 110, 114–15, 116–17
 - patentability 93(n56), 97, 104, 104(n12), 107(n21), 108, 110, 114–15, 115(n51), 116

- pharming and pharm animals 117–18
welfare 97, 104, 110, 114, 117
- antiretroviral medicines 50(*n*33), 56, 57,
58, 155, 156, 161, 161(*n*80), 177(*n*19),
184, 185
- assumed consent (*see* consent: assumed
consent)
- AstraZeneca v Commission* Case T-321/05
84(*n*20)
- ATryn 117–18
- authorship and creator-function 11, 13,
25–6, 41, 102–4, 114–15, 127
- autonomy 143, 146, 156, 189
individual and private 9, 41, 54, 101,
106, 117, 136, 164, 169
national 77
political 41
- Avastin 183
- avian influenza 126, 137(*n*66), 163–9 (*see*
also influenza; viruses)
Indonesia, 74, 74(*n*52), 121, 163–9
Thailand, 163, 164, 167–9
- base material (*see* starting material and
co-invention)
- Baxter Healthcare 164–5
- Bayer 183
- Bayh-Dole Act (*see* United States: Bayh-
Dole Act)
- beneficial interest or right 2, 14, 37–8, 77,
80, 97, 118, 123–4, 135, 137, 145–7,
153, 156, 169, 174, 178–9, 183–4,
185, 187, 192
- benefits, medical and scientific 17, 24–5,
25(*n*22), 26, 32, 43, 44, 46(*n*14), 55,
59, 63–4, 66, 68–9, 73–7, 80–81,
89–90, 95, 97, 110, 118–19, 120–21,
124–9, 135–7, 142, 162, 164–9, 173,
175, 185, 189–90, 192–3 (*see also*
substantial medical benefit)
pricing of medicines 142, 178, 183–4
- Bermuda Accord 135, 136
- Berne Convention for the Protection of
Literary and Artistic Works (1886),
Article 6*bis* 11
- Bevacizumab 183
- bilateralism 56–7, 58, 65–6, 73(*n*48), 75,
82(*n*11), 83, 147, 157, 165, 167
- Bill and Melinda Gates Foundation
134(*n*53)
- biocolonialism 136
- bioethics 93–4
- biologics 91–2
- biomedicines 67, 91 (*see also* biologics)
- biopharmaceuticals 91, 133 (*see also*
biologics)
- bioprospecting and biopiracy 42, 73,
74(*n*56), 107, 123, 127, 128, 130,
164
- biosimilars 91–2 (*see also* biologics)
- biotechnology 13, 13(*n*36), 22, 28–9,
29(*n*43), 30–38, 91–4, 94(*n*59), 97,
101–18, 146
indigenous and local communities
130–31, 130(*n*31)
property and invention 13–14, 28–9,
32–3, 103–4, 106–7, 108, 110, 123,
126(*n*20), 131
- Biotechnology Directive (98/44/
EC) on the legal protection of
biotechnological inventions 13(*n*36),
29–30, 30(*n*47), 31, 34, 103, 106–10
Article 5 29, 30, 106
Article 6 97, 103, 108, 110
Article 11 115(*n*51)
Article 16 111
Recital 14 109
Recital 23 30, 31(*n*54),
Recital 24 30, 30(*n*48)
Recital 25 30
Recital 26 107
Recital 27 107(*n*21)
Recital 38 110
Recital 45 97
Recitals 46–50 115(*n*51)
- Report, An assessment of the
implications for basic genetic
engineering research of failure
to publish, or late publication of,
papers on subjects which could
be patentable under Article 16(b)
of Directive 98/44/EC (2002) 111,
111(*n*35)
- Report from the Commission to
the European Parliament and
the Council, Development and

- Implications of Patent Law in the Field of Biotechnology and Genetic Engineering (2002) 34, 111, 112
- Report from the Commission to the Council and the European Parliament, Development and Implications of Patent Law in the Field of Biotechnology and Genetic Engineering (2005) 29–30, 29(*n*43), 30(*n*44), 113, 114
- body
- integrity 7, 11, 105
 - no-property rule 126, 126(*n*20)
 - property and commodification 106, 123–26, 127
- Bolar exception 181, 192(*n*80)
- Bonn Guidelines on Access to Genetic Resources and Fair and Equitable Sharing of the Benefits Arising out of their Utilization (2002) 76 (*see also* Convention on Biological Diversity (CBD))
- Borges, Jorge-Luis 102
- Brazil 15(*n*42) 16, 156–7
- breach of confidence (*see* confidential information and confidence)
- Bristol-Myers-Squibb 161
- British Adopted Names (BAN) 187
- bulk procurement programmes 58, 142, 179–80
- Canada 35–6, 114–17, 192, 192(*n*80) (*see also* WTO: Rwanda-Canada Notification)
- Canadian Access to Medicines Regime (CAMR) 154–5
- Canadian Biotechnology Advisory Committee on the Patenting of Higher Life Forms 109
- Canadian Institutes of Health Research (CIHR) 134(*n*53)
- Canadian Intellectual Property Office (CIPO) 116
- Jean Chrétien Pledge to Africa 2004 (Food and Drugs Act 2004) 155(*n*47)
- Patent Act 116, 116(*n*47)
- Patented Medicines (Notice of Compliance) Regulations 35–6
- Cancer Patients Aid Association 159
- Cancer Research UK 183
- Canguilhem, Georges 5, 9
- capitalism 81, 84
- Case No 4183/98 18 February 1998 (South African medicines case) 157–9 (*see also* South Africa)
- CBD (*see* United Nations: Convention on Biological Diversity (CBD))
- CDIP (*see* World Intellectual Property Organization (WIPO): Committee for Development and Intellectual Property)
- CESCR (*see* United Nations: Committee on Economic Social and Cultural Rights (CESCR))
- Chan, Dr Margaret, WHO Director-General 55
- children and child mortality 16, 43, 45, 50, 89, 158
- civil society 1–2, 7, 9, 15(*n*42), 19, 20(*n*11), 52, 56(*n*63), 59, 63(*n*9), 70, 88, 120, 129–30, 141, 143–4, 144(*n*12), 156, 158, 163, 168, 169, 183–4, 189–90, 192
- Civil Society Initiative (CSI) (*see* World Health Organization (WHO): Civil Society Initiative (CSI))
- clinical and testing data and trials 85–92, 176, 181, 182
- cloning 91, 97, 105, 107, 110, 112
- Clopidogrel 161, 161(*n*80)
- co-invention 126–7, 128 (*see also* starting material and co-invention)
- collection and sampling 55, 106, 123, 125, 131–2, 134 (*see also* databases)
- collective and consensus 16, 62–3, 70, 79–80, 83, 85, 93, 95, 96, 119, 171
- Colombia 162–63
- colonialism 82, 83(*n*15), 83–4, 130–31, 136, 171–2
- colony, intellectual property 5–6
- commercial will (*see* will: commercial)
- Commission on Human Rights (*see* United Nations: Commission on Human Rights)

- Committee on Economic Social and Cultural Rights (CESCR) (*see* United Nations: Committee on Economic Social and Cultural Rights (CESCR))
- commodification 22–3, 94, 121, 126
 life 11, 22, 41–2, 102, 114–15, 124
 private sphere 121, 124
- common heritage 103
- communicable diseases 43, 52, 162
- communicative action and practice 7, 22, 27, 38, 41(*n*1), 42, 62, 83, 93(*n*56), 143–4
- community 29, 42, 53–4, 55, 67, 71–2, 74(*n*56), 74–5, 80, 93, 119, 121, 125, 126–7, 128, 130–31, 136, 171
 traditional and indigenous
 communities 71–3, 74(*n*56), 75, 124, 125, 128–31
- Community Patent Convention (*see* European Union: Community Patent Convention)
- competition 12, 24, 31(*n*53), 38, 67, 84(*n*20), 85, 88, 90, 92, 96(*n*66), 104–5(*n*13), 148, 157, 161–2(*n*80), 162, 172, 177, 180, 184–6, 188–9, 188(*n*63), 191
- compulsory licensing 2, 20, 52, 56–7, 87, 146–56, 161–3, 161(*n*79), 161–2(*n*80), 179, 179(*n*26), 180
- compulsory purchase 123
- confidential information and confidence 48, 80, 122, 137 (*see also* trade secrets)
- Congress of South African Trade Unions (COSATU) (*see* South Africa: Congress of South African Trade Unions (COSATU))
- consent 106, 125–6, 129, 131, 133–4, 135, 136(*n*62), 147
 assumed 133–4
 community 136
 fresh 125, 134
 prior informed 75, 76, 77, 94–5(*n*60), 107, 109, 125, 126, 133, 134, 135, 135(*n*55), 165–6, 167
- consumer 23, 26, 28, 34–8
- consumption 16, 26
- Convention on Biological Diversity (*see* United Nations: Convention on Biological Diversity (CBD))
- conversion 125–6
- copyright 11, 23, 24, 25, 121(*n*7)
- coronary disease 52–3, 161, 162
- Council on Health Research for Development (COHRED) 141–2
- creative industries 6, 7, 23
- crisis 2, 7–9, 80
- cross-licensing (*see* patent pools)
- cultural identity 54, 72, 173
- cultural life (*see* right to cultural life)
- data exclusivity 57(*n*65), 85, 87–90, 92, 175
- data protection 122–3
- databases 106, 118, 119, 123, 131–7 (*see also* deCODE genetics Inc.; Icelandic Health Sector Database; MalariaGEN; UK BioBank)
- Decision on Paragraph 6 (*see* World Health Organization (WTO): Decision on Paragraph 6)
- Declaration of Alma-Ata (*see* World Health Organization (WHO): Declaration of Alma-Ata)
- Declaration of Commitment on HIV/AIDS (*see* United Nations: General Assembly: UNGASS)
- Declaration on the Right to Development (*see* United Nations: Declaration on the Right to Development)
- deCODE genetics Inc. 133–4, 133(*n*47), 136(*n*62)
- democracy 16, 25, 41, 62, 64, 82–3, 94, 95, 134
 property 1–2, 41–2, 62, 79–80, 143, 171, 173
 public sphere 16, 41, 79, 124, 172
- developed and industrialised countries 16, 19, 21, 66, 81–3, 116, 151, 153, 164, 178, 182
- developing countries 12, 14, 15, 15(*n*42), 16, 19, 21, 24–5, 50, 51–2, 53, 58, 59, 65–7, 67(*n*27), 69–70, 72, 74, 76, 80–82, 84, 107, 134, 135, 136, 141–2, 144, 147, 151, 153, 155, 164, 167, 178–9, 179(*n*26), 181–2, 191

- development agenda 15(*n42*), 44, 50, 65, 66, 149 (*see also* right to development; United Nations: Declaration on the Right to Development)
- diabetes 53, 162, 185
- differential pricing (*see* pricing: differential or tiered)
- dignity 64, 103, 108–9, 110, 114, 121, 158
- disclosure of origin 76, 77(*n61*), 107, 107(*n21*)
- discoveries (*see* patents: discoveries)
- disease and equilibrium 7–8, 9
- Doha Declaration on the TRIPS Agreement and Public Health, 2001 (*see* World Trade Organization (WTO): Doha Declaration on the TRIPS Agreement and Public Health)
- Doha Development Agenda (*see* World Trade Organization (WTO): Doha Development Agenda)
- Doha Ministerial Declaration 2001 (*see* World Trade Organization (WTO): Doha Ministerial Declaration 2001)
- donation and donor material 74, 106, 119, 125, 127, 128, 132, 133, 134, 135, 137, 164–6
- drug donation 53, 158
- ECHR (*see* European Convention on Human Rights)
- Economic rights (*see* Intellectual property: Economic rights)
- ECOSOC (*see* United Nations: Economic and Social Council (ECOSOC))
- education 120
 - access to 9, 15(*n42*)
 - health and 46, 54, 59, 62, 141, 141(*n1*)
 - Millennium Development Goals and 50
 - right to 44(*n9*)
- Edwards, Sen John 191
- Efavirenz 161–2
- efficacy 87, 88, 159–60, 175, 185
- efficiency 15, 32(*n55*), 37, 119, 120, 121
- Eisai/Second Medical Indication* (G-05/83) [1979–85] B EPOR 241 25(*n26*), 33(*n56*)
- embryo research 97, 107, 110, 114–15
- eminent domain 123
- entrepreneur 32, 34
- epidemics 45, 46, 147, 150 (*see also* pandemics)
- equality 47 (*see also* access: equality)
 - gender 50, 70
 - India 160
- equitable interest or right 2, 145, 146(*n19*), 189 (*see also* beneficial interest or right)
- Essential Action, Access to Medicines Project 163
- Essential Inventions 189
- Essential Medicines Licensing Agency (EMILA) 188
- Essential Medicines List (*see* WHO: Essential Medicines List (EML))
- Essential Patent Pool for AIDS (EPPA) 189
- ETC Group 129(*n25*) (*see also* RAFI)
- ethical oversight 7, 13, 80, 94, 109
- ethical and moral priority 81, 119–20
 - intellectual property 7, 11, 24
 - market and investment 12, 81, 171
 - medicine and science 12, 23, 28, 81, 119–20, 130–31
 - private property 1, 12, 41–2
- Ethox Centre, University of Oxford 134
- EuropaBio (European Association for Bioindustries) 91(*n49*), 92(*n53*)
- European Convention on Human Rights (ECHR) 110
 - Article 8 134
- European Generics Association (EGA) *Handbook on Biosimilar Medicines* 2007 92(*n54*)
- European Group on Ethics in Science and New Technologies (EGE) 107, 112
- European Medicines Agency (EMA) 118, 176
 - Committee for Medicinal Products for Human Use (CMPH) 118
- European Patent Convention (EPC) 27(*n39*), 30, 30(*n47*), 33, 93(*n56*), 97(*n70*), 108, 110
 - Article 52 26(*n30*), 26(*n32*), 26(*n32*), 93(*n56*)

- Article 52.2(a) 26(*n*29), 105(*n*14)
 Article 53 110(*n*31)
 Article 53(a) 93(*n*57), 95(*n*62), 97,
 108(*n*27), 110, 110(*n*33),
 Article 53(c) 93(*n*56)
 Article 54 26(*n*31)
 Article 56 26(*n*32)
 Article 57 23(*n*19)
 Article 62 11(*n*29), 11(*n*30), 102(*n*3)
 Article 63 27(*n*37), 86
 Article 83 27(*n*35), 93(*n*56)
 EPC 2000 33
 EPC Rules 11(*n*30), 30(*n*47), 95(*n*62),
 97(*nm*71–4), 97(*nm*76–7)
 European Patent Office (EPO) 25, 34, 97,
 110, 110(*n*32), 115
 Guidelines for Examination in the
 European Patent Office 30(*n*49),
 95(*n*62), 96, 96(*n*66), 96(*n*69), 97,
 97(*n*70)
 Implementing Regulations to the
 Convention on the Grant of
 European Patents (*see* European
 Patent Convention (EPC): EPC
 Rules)
 European Union
 Biotechnology Directive (98/44/EC)
 (*see* Biotechnology Directive
 (98/44/EC))
 Community Patent Convention (CPC)
 27(*n*39)
 Directive 2001/83/EC of 6 November
 2001 on the Community code
 relating to medicinal products for
 human use 87(*n*32), 88,
 88(*nm*33–4), 89(*n*40), 91(*n*47),
 92, 92(*nm*51–2), 176, 176(*n*13),
 176(*n*15), 186, 186(*nm*57–9), 187
 Directive 2003/63/EC of 25 June 2003
 amending Directive 2001/83/EC
 on the Community code relating
 to medicinal products for human
 use 92(*n*51)
 Directive 2004/27/EC of 31 March
 2004 amending Directive 2001/83/
 EC on the Community code
 relating to medicinal products for
 human use 88(*nm*33–5), 89(*n*40),
 91(*n*47), 92(*n*52)
 Directive 95/46/EC of 24 October 1995
 on the protection of individuals
 with regard to the processing of
 personal data and on the free
 movement of such data
 122–3(*nm*10–11)
 EC Treaty 84(*n*20), 108(*n*25)
 EEA Agreement 84(*n*20)
 Opinion No 15 Ethical Aspects of
 Human Stem Cell Research and
 Use, 14 November 2000 112,
 112(*n*40)
 Opinion No 16 Ethical Aspects of
 Patenting Inventions Involving
 Human Stem Cells, 7 May 2002
 112, 112(*nm*41–3)
 Regulation (EEC) No 1768/92 of 18
 June 1992 concerning the creation
 of a supplementary protection
 certificate for medicinal products
 86(*nm*25–6), 87(*n*27)
 Regulation (EC) No 1610/96 of 23
 July 1996 concerning the creation
 of a supplementary protection
 certificate for plant protection
 products 86(*n*25)
 Regulation (EC) No 816/2006 of
 17 May 2006 on compulsory
 licensing of patents relating to the
 manufacture of pharmaceutical
 products for export to countries
 with public health problems 151,
 151(*n*33), 155, 155(*n*49)
 Regulation (EC) No 1901/2006 of
 12 December 2006 on medicinal
 products for paediatric use
 87(*n*32), 89, 89(*n*38), 89(*n*40),
 90(*n*44)
 excludability and non-excludability 80,
 82, 95, 171 (*see also* public good)
 Exclusive Marketing Rights (EMR) 159
 Expanded Programme on Immunization
 (EPI) 179
 experimental use (*see* patents:
 experimental use)
 FDA (*see* United States: Food and Drug
 Administration (FDA))

- feedback 132, 132(*n*41), 136(*n*64), 137
 feoffees in trust 172
 feudalism and feudal tenure 145, 172–3
 fiduciary duty 125
 free trade agreements (FTA) 57, 57(*n*65),
 65–6, 73, 73(*n*49), 172 (*see also*
 bilateralism; multilateralism)
 freedom of research 29, 34, 111
 fresh consent (*see* consent: fresh consent)
- Gay Men's Health Crisis (GMHC) 158
 gender 48, 67, 120 (*see also* equality)
 gene patents and gene-related inventions
 13, 22, 25–6, 28–32, 32(*n*55), 33–8,
 69(*n*35), 101, 104, 105, 106, 107,
 113–14, 127, 146 (*see also* life
 patent)
 gene sequence (*see* gene patents and
 gene-related inventions)
 Genentech 183
 generic names 184–7 (*see also* INN)
 generics 20(*n*11), 20, 21, 36, 53, 58, 84–5,
 84(*n*19), 84(*nn*21–2), 87–88, 90,
 90(*n*43), 91–2, 151, 153–5, 157, 159,
 161–3, 180, 181, 186, 188, 191
 Generics (UK) 84(*n*22)
 genetic databases (*see* databases)
 genetic identity 97, 104, 106, 110, 131
 genetic imperialism 107 (*see also*
 biocolonialism)
 genetic information 103, 127, 133
 genetic material 7, 42, 103, 105, 106, 107,
 115, 117, 123, 127, 131, 135, 166, 169
 genetic resources (*see also* bioprospecting
 and biopiracy; Bonn Guidelines;
 United Nations: Convention on
 Biological Diversity) 107, 119, 121,
 123–5
 access and benefit sharing 15, 71–2, 73,
 74, 74(*n*53), 75–6, 129, 137, 163–8
 avian influenza, 74, 74(*n*52), 163–8
 equitable management, 71–2, 73, 75–6
 expropriation and misappropriation,
 75, 106
 individual 123–4, 126–7
 invention 126–8
 sovereignty and national sovereignty
 62, 73, 75, 119, 166
- traditional and indigenous knowledge
 71–2, 72(*n*43), 73, 73(*n*48), 75, 106,
 127–8, 130(*n*31)
 genetically-modified crops and
 agriculture 104–5(*n*13)
 Genetics Institute Inc. 125
 genome 102–3
 genome-wide association studies 55, 123,
 131, 132, 133, 134
 germ line technology 97, 110
 Germany, 20
 GISN (*see* World Health Organization
 (WHO): Global Influenza Sharing
 Network (GISN))
 GlaxoSmithKline (*see* GSK)
 Gleevec (*see* Glivec)
 Glivec 159–60
 Global Fund for Essential Inventions 189
 Global Fund to Fight AIDS,
 Tuberculosis and Malaria (GFATM)
 56, 56(*n*63)
 global health agenda 17, 19
 global health equity 1, 2, 15, 16, 52, 144,
 161, 193
 Global Influenza Sharing Network (*see*
 World Health Organization (WHO):
 Global Influenza Sharing Network
 (GISN))
 global medicines trust 2, 145
 globalisation 10, 19, 41, 191
 Goldshield Group 84(*n*22)
Gowers Review of Intellectual Property
 2006 (*see* United Kingdom: *Gowers*
Review of Intellectual Property 2006)
 Grand Challenges in Global Health
 (GCGH) 134, 134(*n*53)
 Greenpeace 107
 GSK 84(*n*21), 157–9, 163, 184
 GTC Biotherapeutics 118
- Habermas, Jürgen 7, 16, 41, 41(*n*1), 62,
 83(*n*15), 103, 119–20
 Hagahai 128–9, 129(*nn*26–7)
 hairy-cell leukaemia 124
 Haiti 54(*n*53)
 harmony and equilibrium 9, 24, 79
Harvard College v Canada (Commissioner
of Patents) [1998] 3 FC 510 116(*n*53)

- Harvard College v Canada (Commissioner of Patents)* [2000] 4 FC 528 116(n54)
- Harvard College v Canada (Commissioner of Patents)* [2002] SCC 76 116(n56), 116(n58)
- Harvard oncomouse 104(n12), 110, 115–17
- Harvard/Onco-mouse* (T-19/90) [1990] EPOR 501 97(n76), 110
- Harvard/Transgenic Animal* (T-315/03) [2005] EPOR 31 115(n52)
- Hatch-Waxman Act (*see* United States, Hatch-Waxman Act)
- health (*see also* right to health)
- cultural identity 54, 72, 173
 - cultural life 38(n69), 59–60, 67–72, 79, 80, 97, 172, 173, 192
 - definition 9–10, 11, 42–4, 54, 79, 173
 - development 10, 44, 61, 83, 84
 - economic good 14, 80, 82, 84
 - life chances and social status 2, 8–10, 8(n12), 15–16, 41, 47, 48, 52, 83–4, 141, 173, 175
 - public good 43, 44, 80–82, 185, 192
 - social and mental well-being 10, 17, 42–3, 44, 45, 54, 61, 63, 64, 79, 81, 173
- Health GAP Coalition 158
- Health Impact Fund 142
- health institutions (*see* institution: health)
- hereditary antithrombin deficiency (HAD) 117
- heritage (*see* common heritage)
- highly active antiretroviral treatment (HAART) 184
- HIV/AIDS 14, 46, 49–51, 50(n33), 54(nn53–4), 55–9, 136(n64), 141(n1), 150, 155, 156–8, 161–3, 183–4
- IVI International AIDS Conference Toronto 2006 156–7, 177
- XVII International AIDS Conference Mexico City 2008 54(n53), 177(n19), 189
- (*see also* United Nations: United Nations Joint Programme on HIV/AIDS (UNAIDS))
- Howard Florey/Relaxin* [1995] EPOR 541 96(n68)
- Hubbard, Tim 190(n69)
- Human Genome Organisation (HUGO) 135(n57)
- Human Genome Project 135
- human rights (*see* right to benefit; right to cultural life; right to development; right to health)
- Human Rights Council (*see* United Nations: Human Rights Council)
- Husserl, Edmund 24
- Iceland (*see also* deCODE genetics Inc)
- Icelandic Act on Biobanks 133
 - Icelandic Health Sector Database (HSD) 133
 - Icelandic Supreme Court No 141/2003 133, 133(n50)
- ICESCR (*see* United Nations: International Covenant on Economic, Social and Cultural Rights (ICESCR))
- Icos Corporation/Seven transmembrane receptor* [2002] OJEPO 293 30(n49)
- ILO (*see* United Nations: International Labour Organization (ILO))
- Imatinib 159
- IMS Health 84–5, 85(n23)
- In re Abbott Laboratories Norvir Anti-Trust Litigation*, 562 F.Supp.2d 1080 (ND Cal 2008) 184, 184(n47)
- incentives 14, 22, 23, 24, 32(n55), 37, 66, 69, 89, 105, 131, 136, 142, 175, 178, 181–2, 182(n37), 188, 190–91
- Incentives for Global Health (IGH) 142, 142(n5)
- India 19–21, 77(n61), 159–63
- indigenous peoples 42, 49, 54(n53), 64, 70, 71–2, 106, 124, 128, 130, 130(n31)
- Indigenous Peoples' Council on Biocolonialism (IPCBI) 130(n31)
- Indonesia (*see* avian influenza: Indonesia)
- industrial application or utility (*see* patents: industrial application)
- infectious diseases (*see* communicable diseases)

- influenza (*see also* avian influenza; viruses)
 WHO Collaborating Centres (CC) 163, 168, 168(*n*100), 169
 WHO Global Influenza Surveillance Network (GISN) 74(*n*52), 163–4
 WHO H5 Reference Laboratory Network 164
 WHO Intergovernmental Meeting on Pandemic Influenza Preparedness (PIP) 74(*n*52), 165–8
 WHO Laboratories, Terms of Reference 164, 165, 166, 168(*n*100)
 WHO National Influenza Centres (NIC) 163
 WHO Pandemic Influenza Preparedness (PIP) 74(*n*52), 165–6
- informed consent (*see* consent: informed consent)
- inheritance rights 156
- INN (*see* International Nonproprietary Name (INN))
- INNМ (*see* International Nonproprietary Name (modified) (INNМ))
- innovation/creativity dichotomy 22(*n*16), 24
- institution 5, 24, 95
 health 2, 24, 41, 49, 79, 80, 85, 134, 192
 intellectual property and patent system 24, 79, 83(*n*15), 85, 95, 192, 193
 public 79, 120, 143–4, 156, 158, 180, 189, 192, 193
 science and technology 81, 85
- intellectual property
 bargain and social contract 27, 28, 32
 charisma 13, 13(*n*35)
 colonial discourse 82, 83, 83(*n*15), 171–2
 colony 5–6
 economic rights 11, 41
 ethical oversight 7, 13, 80, 109
 institution (*see* institution: intellectual property and patent system)
 liberties 93, 121
 map of innovation 11, 13, 83, 103
 organism and organic unity 5–6, 8–10, 11, 15, 34, 79, 103
 religious rhetoric and reverence 12, 13, 13(*n*35), 131
 rights, expansion and strengthening 6, 12, 19, 21, 81
 narrative of innovation 21–2, 24, 82
- International Cooperative Biodiversity Group (ICBG) 75
- International Covenant on Economic, Social and Cultural Rights (*see* United Nations: International Covenant on Economic Social and Cultural Rights (ICESCR))
- International Labour Organization (*see* United Nations: International Labour Organization (ILO))
- International Nonproprietary Name (Modified) (INNМ) 185(*n*51)
- International Nonproprietary Name (INN) 159, 185–7, 185(*n*51) (*see also* British Adopted Names)
- WHO Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparation 186
- WHO *Guidelines on the Use of International Nonproprietary Names (INNs) for Pharmaceutical Substances* 185(*n*52)
- World Health Assembly Resolution WHA3.11 185(*n*51)
- World Health Assembly Resolution WHA31.32 184–5, 185(*n*50)
- inventorship 28, 104, 104(*n*12), 128, 166
- investment 12, 14, 24, 31, 32, 34, 37, 81, 84, 85, 87, 90, 127, 141–2, 178
- Jackson, Moana, 130(*n*33)
- Jeremy Buck's patent of 1651 for the smelting of iron with coal 27(*n*36)
- Joint United Nations Programme on HIV/AIDS (*see* United Nations: Joint Programme on HIV/AIDS (UNAIDS))
- Kaletra 161, 161(*n*80), 163, 184
- KEI 188, 191, 191(*n*76)
- Kent Pharmaceuticals 84(*n*22)
- Kingdom of Netherlands v European Parliament and Council of European*

- Union (C-377/98)* [2001] 3 CMLR 49 108(*n*24), 108(*n*27), 109(*n*28), 111(*n*37–38)
- Kirin-Amgen Inc. v Hoechst Marion Roussel* [2004] UKHL 46 33
- Knowledge Ecology International (*see* KEI)
- knowledge economy 1, 6, 9, 12, 13, 38, 79, 81, 83, 171–2
- knowledge transfer 71, 72, 82, 156, 164 (*see also* technology: transfer)
- known substance (*see* patents: known substance)
- labelling 26, 36, 37, 89(*n*42), 113, 152, 175, 186–7 (*see also* International Nonproprietary Name (INN))
- Lamivudine 155
- land 145, 156, 171, 172–3
- Lao People's Democratic Republic 74
- least-developed countries 21, 76(*n*59), 149, 151, 153, 154–5, 155(*n*45)
- Lebenschancen* 8 (*see also* life chances)
- Lebensführung* 9 (*see also* life conduct)
- Lebensstil* 9 (*see also* lifestyle)
- Lebenswelt* 7 (*see also* lifeworld)
- Leech and the Earthworm, The* (2003) 130–31
- legitimacy and legitimation 1–2, 11, 16, 28, 41, 42, 55, 62, 77, 79, 82, 83, 94, 95, 119, 142, 144, 189
- leukaemia (*see also* hairy-cell leukaemia) 124–5, 128
- liberties 62, 93, 106, 121, 172
- life chances 2, 8, 8(*n*14), 9–10, 15–16, 23, 28, 41, 47, 48, 52, 62, 69, 80, 83–84, 141, 173, 175
- life conduct, conduct of life 9
- life form 101, 104(*n*12), 107, 109, 116–17
- life patent 11, 13, 101, 102, 103 (*see also* gene patent)
- lifestyle 9
- lifeworld 7, 8, 9, 13, 17, 24, 83, 83(*n*15), 103, 143
- living material (*see* tissue and living material)
- Lopinavir 161, 161(*n*80), 163
- Love, James 190(*n*69)
- Mahler, Dr Halfden, former WHO Director-General 55
- malaria 50, 56, 59, 128, 129, 134–7, 150, 185
- Malaria Genomic Epidemiology Network (*see* MalariaGEN)
- MalariaGEN 134–7
- Malawi 54(*n*54)
- manufacture and production capacity, 20, 150–51, 153–5, 155(*n*45), 169
- Māori 130, 130(*n*33), 171
- mapping and identity 102–3 (*see also* genetic identity)
- March-in right (*see* United States: Bayh-Dole Act)
- market and research agenda 9, 14, 80–82, 83–4, 85, 94 (*see also* research and development)
- market exclusivity 56–7, 87, 88, 89, 181, 191, 192
- Massachusetts Institute of Technology (C-431/04)* [2006] RPC 34 86(*n*28)
- Material Transfer Agreement (MTA) 165, 166, 167
- maternal health 50, 51
- MDG (*see* United Nations: United Nations Development Programme: Millennium Development Goals (MDG))
- Médecins Sans Frontières (*see* MSF)
- Medical Research and Development Treaty (MRDT) 190
- Meijer Inc v Abbott Laboratories*, 544 F.Supp.2d 995 (ND Cal 2008) 184(*n*49)
- Meijer Inc v Abbott Laboratories*, Slip Copy (ND Cal August 27 2008) 184(*n*47)
- Merck 161, 162
- Merrell Dow Pharmaceuticals Inc. v HN Norton & Co. Ltd* [1996] RPC 76 (HL) 27(*n*40), 33, 33(*n*57–58)
- Millennium Declaration (*see* United Nations: Millennium Declaration)
- Millennium Development Goals (*see* United Nations: United Nations Development Programme: Millennium Development Goals (MDG))

- misinformation 130–31
MobilFriction reducing additive (G-02/88) [1990] EPOR 73, EBA 25(n26), 34, 34(n61)
Moore v Regents of the University of California, 51 Cal. 3rd 120 (California Supreme Court 1990) 124–27
 morality and law 42, 58, 93, 94, 109, 110
 moral rights 11, 41
 morality and public order (*see ordre public*)
 most-favoured nation principle 57, 82(n11), 83
 MSF 141, 161–2(n80)
 multilateralism 57, 65, 73(n48), 82(n11), 83 (*see also* bilateralism; free trade agreements)
- National Institutes of Health (*see* United States: National Institutes of Health (NIH))
 neglected and rare diseases 14, 52, 83, 181, 182
 Netherlands 108–9
 Nevirapine 155
 new chemical entities (NCEs) 88(n33), 89(n42)
 Nexavar 183
 NHS (*see* United Kingdom: National Health Service (NHS))
 NICE (*see* United Kingdom: National Institute for Clinical Excellence (NICE))
 NIH (*see* United States: National Institutes of Health (NIH))
 no-property rule (*see* body: no-property rule)
 norm cascade 120, 189 (*see also* civil society)
 Norton Healthcare 84(n22)
 Norvir 184
 Novartis 159–61
Novartis AG & Anr v Union of India & Others (2007) 4 MLJ 1153 160(n73)
 Nuffield Council on Bioethics, *The Ethics of Patenting DNA*, 2002 28, 28(n41), 103
- Office of Fair Trading (*see* United Kingdom: Office of Fair Trading (OFT))
 OHCHR (*see* United Nations: Office of the High Commissioner for Human Right (OHCHR))
 oncogene 115
 oncomouse (*see* Harvard oncomouse)
ordre public 93, 94(n58), 95, 95(n62), 96–7, 108, 110, 110(n32), 111, 116
 orphan diseases (*see* neglected and rare diseases)
 orphan drugs 89, 142, 181
 ownership 13, 37, 42, 79, 102–4, 104(n12), 106, 115, 117, 120, 124, 126, 127, 166, 173
- Oxfam, *Investing for Life: Meeting Poor People's Needs for Access to Medicines Through Responsible Business Models* (2007) 14(n37)
- paediatric medicine 87, 89, 89(n42), 90
 Pan-American Health Organization (PAHO) 179
 Pandemic Influenza Preparedness (*see* World Health Organization (WHO): Pandemic Influenza Preparedness (PIP)) (*see also* Avian Influenza; Influenza)
 pandemics 50, 51, 55–6, 58, 74(n52), 163, 165, 169
 Papua New Guinea 128
 Paragraph 6 System (*see* World Trade Organization (WTO): Paragraph 6 System)
 parallel importation 52, 157, 179
 Paris Convention for the Protection of Industrial Property (1883) 29(n29), 95(n61), 102(n3), 147, 148
Parke, Davis & Co v The Comptroller General of Patents, etc., 71 RPC 169 20(n7)
 patent pools 67, 142, 187, 188–9, 188(n63)
 patent system
 ethical oversight 13, 80, 109
 morality 109–13
 two cultures 23–4

- patentability 22, 26, 31–4, 37, 56, 93–4, 94(*n*58), 94–5(*n*60), 95–6, 96(*n*66), 97, 104, 105, 106–7, 109, 110, 112, 113, 114, 115, 159
- patents (*see also* gene patents)
 access to knowledge 81, 171
 bad 6, 6(*n*6)
 chemical 19–20, 19(*n*2), 20(*n*9), 30, 82(*n*12), 86, 86(*n*29), 91
 classical or absolute protection 32, 32(*n*55), 34, 69(*n*35), 113–14
 competition 12, 24, 188, 191
 contract 24, 27, 28
 cultural value and use 22, 23, 24, 26, 27, 93(*n*56), 102
 disclosure 22, 27–8, 30, 32–3, 36, 76, 77(*n*61), 93(*n*56), 107, 107(*n*21), 112–13, 114, 122, 127
 discoveries 26, 31, 32, 93(*n*56), 105–6, 107, 113, 129, 159
 exclusive rights 27, 27(*n*39), 104, 124, 147, 192
 experimental use and research
 exception 93, 93(*n*56), 181, 192
 failure to work 147–8
 indices of innovation 6, 13(*n*34), 37, 81, 82
 industrial application 23, 26, 27, 30, 31(*n*52), 33, 105, 112, 160
 known substance 26, 33, 34, 159, 160
 person skilled in the art 27, 33, 33(*n*60), 93(*n*56), 160
 purpose-bound protection 2, 22, 28, 29, 29(*n*43), 33–8, 69(*n*35), 113, 114
 technical solution 23, 26, 27, 29
 term restoration 180–81
- People's Health Movement (PHM) 55
- Permanent Forum on Indigenous Issues (PFII) 70
- person skilled in the art (*see* patents)
- personal rights 124–5
- Pfizer 158, 183
- Pharmaceutical Research and Manufacturers of America (PhRMA) 157
- Pharmascience v Sanofi-Aventis* (2006) FCA 229 35–6
- pharming and pharm animals (*see* animals: pharming and pharm animals)
- plant protection and plant varieties 27, 86, 86(*n*25), 86(*n*29), 104–5(*n*13), 107
- Plavix 161
- Political Declaration on HIV/AIDS (*see* United Nations: Political Declaration on HIV/AIDS)
- political will (*see* will: political)
- population studies (*see* genome-wide association studies)
- Portuguese Man o' War 5
- possession 2, 9, 125, 126, 131, 146, 172
 use 2, 146, 172–3, 174
- poverty 10, 16, 25, 49, 59, 67
- POZ (*see* Promoteurs Objectif Zero Sida (POZ))
- PPRS (*see* United Kingdom: Pharmaceutical Price Regulation Scheme)
- Prescription Access Litigation (PAL) 184
- pricing
 benefits, linked to 178, 183, 190
 differential or tiered 52, 178–80
 cost-effectiveness 92, 153, 182–3, 185
 price-fixing 84(*n*22), 157
 profit-cap and price-cut schemes 178
 value-based pricing, 178
- primary health care 46, 53–4, 72, 135, 144
- prior informed consent (*see* consent: prior informed consent)
- priority review voucher 181–2
- privacy 97, 119, 122–3, 125, 131, 133–4
- private property (*see* property: private property)
- privateering and privateers 42, 119, 121
- prizes 142, 190–92, 190(*n*71), 191(*n*77)
- profit and profitability 9, 14, 81, 84, 141, 142, 162, 178, 179, 182, 183, 188, 190, 193
- Promoteurs Objectif Zero Sida (POZ) 54(*n*53)
- property (*see also* body; democracy; public sphere; use)
 personal property 124–5
 private property 1, 41–2, 103, 120, 123–4, 143, 145, 171, 172–3

- Protease inhibitor (PI) 184
 public benefit 81, 121, 123
 public domain 74(*n*56) 128, 186
 public goods
 health, 12, 44, 80–81, 192
 intellectual property 80, 145, 192
 knowledge 82, 93, 95–6, 123, 185, 192
 research and development 80, 119, 124, 145
 public health databases (*see* databases;
 see also genome-wide association
 studies)
 public interest 27, 51, 52, 93(*n*56), 103,
 116, 129, 146, 162, 176
 public sphere 95, 119–20, 134
 access and participation 1–2, 16–17,
 41, 54, 62–4, 70, 79, 120, 124,
 143–4, 156, 169, 172–3, 189–90,
 193
 property 41, 124, 172
 public-private partnership and
 cooperation 56(*n*63), 65, 121, 136
 purpose-bound protection (*see* patents:
 purpose-bound protection)
- R & D (*see* research and development)
 RAFI 129 (*see also* ETC Group)
 Ranbaxy 84(*n*22)
 rare diseases (*see* neglected and rare
 diseases)
 regulatory framework 27, 80, 81–3, 85–8,
 90, 144, 175–6, 176(*n*14), 177, 178,
 180–81
 research agenda (*see* research and
 development)
 research and development 2, 8, 9, 17, 71,
 76, 81, 83–4, 119, 182, 190
 access to benefits 46(*n*14), 52, 63, 66–7,
 69, 77, 142, 149, 190
 investment 12, 81, 85, 90, 141, 158
 markets and profitability 14, 37, 80, 81,
 83, 85, 87, 89, 141, 142, 146(*n*19),
 174, 181, 183, 191
 patent system 66, 85, 109, 111, 112,
 142, 190–91
 public good 80, 119
 public-private partnerships 58
 right to benefit 69
 right to cultural life 59, 68–75, 79, 80, 95,
 167, 173
 access to benefits of scientific research
 59, 63, 124, 189
 health 68–71, 172
 right to development 61–6, 63(*n*9)
 health 10, 59, 60, 62, 63, 81, 145
 self-determination 62, 64
 right to health 9–10, 41–60, 61, 63,
 66–71, 72(*n*44), 80–81, 141–6, 149,
 169, 172–4, 187, 189–90
 acceptability 47–8, 59, 70–71, 93, 141,
 141(*n*1), 144–6, 172–5, 189
 access to treatment and health care
 8(*n*12), 42, 47, 49–50, 54, 59,
 69–70, 84, 112, 149, 158, 175, 193
 accessibility 2, 47–9, 56, 59, 66, 67, 71,
 77, 80, 83–4, 118, 141–2, 147, 172,
 174–5, 178, 180, 182, 185
 availability 2, 14, 47–9, 56, 58–9, 61–2,
 67, 118, 136–7, 141–2, 147, 153,
 161, 172, 174–6, 179, 185, 186
 cultural aspects 10–11, 17, 22–3, 25,
 25(*n*22), 38(*n*69), 42–3, 45, 48–9,
 54, 54(*n*53), 54(*n*54), 56, 59–60,
 61, 63–4, 67–77, 72(*n*44), 74(*n*56),
 79–81, 83–4, 95, 97, 101, 141,
 141(*n*1), 144–5, 156, 172–5, 192
 cultural life, right to 42, 59–60, 67–77,
 79, 80, 95, 172–3
 discrimination 43–4, 48, 57, 70, 174
 development, including right to 2, 8,
 10, 12, 14, 15(*n*42), 17, 25, 42–6,
 46(*n*14), 49–50, 50(*n*32), 52–3,
 53(*n*52), 55–6, 59–60, 61–8, 69,
 72, 77, 81, 84, 93, 135, 136, 141–2,
 143–6, 149, 156, 169, 174, 180,
 189–91
 economic aspects 9–10, 14, 15, 15(*n*42),
 16, 21–2, 23, 42–4, 46, 48, 54, 56,
 58, 61, 63–4, 69, 70–72, 80–85,
 134, 144, 146, 167, 174, 176–7,
 179–80, 182–3
 education, including right to 9,
 15(*n*42), 44(*n*9), 46, 49–50, 54, 59,
 62, 141, 141(*n*1)
 environment 8(*n*12), 9, 16, 45, 50, 73,
 75, 107, 110, 110(*n*32)

- food, including right to 44, 44(n9), 46, 54, 62, 71, 156
 four essential elements 47–9, 144, 172–74
 inclusive right (freedoms and entitlements) 44–5, 47–8, 50–51, 61, 63, 69, 80, 144, 173–4, 189
 Millennium Development Goals 49–51, 53, 57–8, 63(n9), 65–6, 81
 prevention programmes 45–6, 51, 54, 54(n53), 56–9, 72, 131–2, 134, 141(n1), 177(n19)
 quality 47–9, 56, 59, 172, 174–5, 182, 185
 sanitation, including right to 50
 underlying determinants of health 8(n12), 15, 45, 48, 48(n25), 59, 61–2, 67, 80, 146
 water 44(n9), 45, 50, 71, 80
 well-being, including mental and social 10, 17, 42–5, 54, 61, 63, 64, 79, 81, 173
 risk (and trust) 2, 5, 85, 87, 110
 Ritonavir 161, 161(n80), 163, 183–4
 Roche 91(n49), 163, 181, 183
Roche Products v Bolar Pharmaceutical Co., 733 F.2d 858 (Fed. Cir. 1984) 181
 Rural Advancement Foundation International (*see* RAFI)
 Rwanda–Canada notification (*see* World Trade Organization (WTO): Rwanda–Canada notification)
 safety 87–8, 96(n65), 117, 134, 175–6, 185–6
 samples and collection 55, 74, 94–5(n60), 106, 119, 121, 123, 125–6, 128–9, 131–5, 137, 163–8 (*see also* avian influenza; bioprospecting and biopiracy; deCODE Genetics Inc., Hagahai patent; MalariaGEN; *Moore v Regents of the University of California*; UK Biobank)
 access and benefit sharing 164–8
 consent 75–7, 94–5(n60), 106, 107, 109, 125, 129, 131, 133–6, 135(n55), 136(n63), 165–7
 genetic resources 74, 106, 119, 164–8
 indigenous and traditional knowledge 73, 106, 128–9
 privacy 119, 125, 131
 property 123–6, 132, 137
 slavery 106
 starting materials and co-invention 73–4, 126–9, 166
 Sanders, Sen Bernie 191
 Sandoz Pharmaceuticals 125
 Sanger Institute 190(n69)
 Sanofi-Aventis 35, 161, 161(n80)
 scarcity 11, 11(n27), 24
 science and technology (*see* institution: science and technology)
 scientific and technological progress 2, 12, 14, 32, 37, 46(n14), 59–60, 63–4, 67–9, 112(n42), 119, 131, 175, 185, 192
 self-determination, right to 62, 64, 95, 109, 189–90
 self-ownership (*see also* individual) 42, 124, 126
 slavery 105, 106
 Snow, Lord 23–4
 socialisation 7, 16, 83
 Sorafenib 183
 South Africa 52(n44), 84(n21), 156–8, 176–7, 177(n19)
 Congress of South African Trade Unions (COSATU) 158
 Health Products Regulatory Authority (proposed) 176
 Medicines and Related Substances Control Amendment Act 1997 157
 Medicines and Related Substances Amendment Bill 2008 176
 Medicines and Related Substances Control Act 1965 157
 Medicines Control Council (MCC) 176, 176(n17)
 Omnibus Trade and Competitiveness Act 1988 157(n55)
 Trade Act 1974 157(n55)
 Uruguay Round Agreements Act 1994 157(n55)
 SouthCentre 155(n48)
 sovereignty 7, 62, 104, 131–2, 149
 community 55, 121, 126–7

- individual subject 8, 105, 121, 123, 126–7
- intellectual property 7, 104, 119, 124
- national sovereignty and genetic resources 62, 73–4, 76, 119
- viral 163–9
- Special Rapporteur on the right to health (*see* United Nations: Special Rapporteur on the right to health)
- starting material and co-invention 28–9, 73–4, 91, 126–9, 166
- status 8, 8(*n*12), 16, 48, 120
- Statute of Monopolies (*see* United Kingdom: Statute of Monopolies)
- stem cells 12(*n*32), 112–14
- Stiglitz, Joseph 190(*n*70)
- stock-piling 163
- Stocrin 161, 162
- subjectivity 8, 11, 24
- subsequent use 94–5(*n*60), 108, 125, 128, 164
- subsidiarity 108
- substantial medical benefit 97, 110, 120
- substitution 31(*n*53), 38, 90, 157
 - substitution, marginal rate of 91
- Sulston, Sir John 136–37
- Sunitinib 183
- supplementary protection certificates 84, 85, 86–7, 86(*m*25–6, *m*28–9), 89, 180
- Sustiva 161
- Sutent 183

- TAC 158, 177
- TAG 158
- Tamiflu 163
- technology 13, 81, 101, 104
 - access to 14, 15(*n*42), 25, 28, 67
 - cultural aspects of 22
 - de-humanising 101–2
 - diffusion and dissemination 24–5, 80, 141–2
 - identity 102–4
 - intellectual property rights 25, 28, 34, 37, 93, 104–5(*n*13), 106–9, 113, 160, 188, 191, 192
 - invention and scope 22, 28, 31(*n*53), 37 101
 - transfer 15(*n*42), 21, 58, 82, 136, 146
- Temsirolimus 183
- Thailand 161–4, 167–9
 - compulsory licences 161–3
 - Government Pharmaceutical Organisation (GPO), 162
 - vaccine facility and avian influenza 163, 168–9
- tiered pricing (*see* pricing: differential or tiered)
- tissue and living material 11, 12(*n*32), 13, 41, 94–5(*n*60), 101, 104, 106, 118–19, 121, 123–7, 131
- Torisel 183
- trade marks 11, 186–7
- trade secrets 80, 122–3, 137, 142–3, 171
- traditional and indigenous communities (*see* community: traditional and indigenous communities)
- traditional cultural expressions 171–2
- traditional knowledge 71–3, 72(*n*43), 73(*n*48), 74(*n*56), 75–7, 106, 107, 121, 127, 130(*n*31), 171–2
- traditional medicine and health care 54, 54(*n*53), 54(*n*54), 71–6, 72(*n*44), 101, 128, 156, 177(*n*19)
- Traditional Medicines Resource Centre (TRMC) 74
- transgenic animals (*see* animals: genetic research and transgenic species)
- transplants 123
- Treatment Access Group (*see* TAG)
- Treatment Action Campaign (*see* TAC)
- TRIPS (*see* World Trade Organization (WTO): Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS))
- TRIPS-plus 147
- tropical diseases (*see* neglected and rare diseases)
- trust 1–2, 5, 5(*n*3), 72, 118, 122, 133, 136–7, 144–6, 161, 164, 172, 192 (*see also* global medicines trust)
 - access and 144–45
 - trustworthiness 2, 122, 137
 - use and 125, 146
- Tshabalala-Msimang, Dr Manto 156, 177(*n*19), 177(*n*22)
- tuberculosis 56, 59, 150, 161–2, 185

- two cultures (*see* patent system: two cultures)
- UDHR (*see* United Nations: Universal Declaration of Human Rights)
- UK Biobank 131–3
- UNAIDS (*see* United Nations: United Nations Joint Programme on HIV/AIDS)
- UNDP (*see* United Nations: United Nations Development Programme)
- UNEP (*see* United Nations: United Nations Environment Programme)
- UNESCO (*see* United Nations: United Nations Educational, Scientific and Cultural Organization)
- UNGASS (*see* United Nations: General Assembly: UNGASS)
- UNHCR (*see* United Nations: United Nations High Commissioner for Refugees)
- UNICEF (*see* United Nations: United Nations Children's Fund)
- UNITAID (*see* World Health Organization (WHO): UNITAID)
- United Kingdom
 Commission on Intellectual Property Rights, *Integrating Intellectual Property Rights and Development Policy* 2002 74(*n*54)
- Examination Guidelines for Patent Applications Relating to Biotechnological Inventions, Intellectual Property Office 2007 30(*n*49)
- Gowers Review of Intellectual Property* 2006 6(*n*6)
- Medicines Act 1968 176(*n*14)
- Medicines and Healthcare Products Regulatory Agency (MHRA) 176(*n*14)
- Medicines for Human Use (Marketing Authorisations Etc.) Regulations 1994 88(*n*33)
- National Health Service (NHS) 84(*n*22), 153, 178, 182
- National Institute for Health and Clinical Excellence (NICE) 85(*n*24), 182–83
- Office of Fair Trading (OFT) 178, 183, 190
- The Pharmaceutical Price Regulation Scheme*, Market Study, 2007 178, 178(*n*23), 183, 183(*n*45)
- Patent Rules 2007 r 10 11(*n*30)
- Patents Act 1919 s 11 19(*n*3)
- Patents Act 1949 20
- Patents Act 1949 s 41 20(*n*6), 148(*n*22)
- Patents Act 1977 20
- Section 13 11(*n*30)
- Section 22 96(*n*65)
- Section 60(5)(a) 93(*n*56)
- Section 60(5)(b) 93(*n*56)
- Section 60(5)(h) 93(*n*56), 115(*n*51)
- Patents and Designs Act 1907 s 38A(1) 19(*n*3)
- Pharmaceutical Price Regulation Scheme (PPRS) 178, 182
- Serious Fraud Office (SFO) 84(*n*22)
- Statute of Monopolies 27
- United Nations
 Commission on Human Rights 49, 49(*n*28), 50, 64–5, 145(*n*15)
 Resolution 1998/72 64
 Resolution 2001/33 50–51
 Resolution 2002/31 49
 Resolution 2004/7 64
- Committee on Economic Social and Cultural Rights (CESCR) 46, 47, 48(*n*25), 54(*n*53), 70–71, 72(*n*44) (*see also* United Nations: International Covenant on Economic Social and Cultural Rights (ICESCR))
- Day of General Discussion (DGD) on the right to take part in cultural life 70–71
- General Comment No. 3. The nature of States parties obligations (Art. 2, para. 1) 46
- General Comment No. 14. The right to the highest attainable standard of health (Art. 12) 47–8, 48(*n*25), 54(*n*53), 61, 72(*n*44), 144, 172, 173, 174
- General Comment No. 16. The Equal Right of Men and

- Women to the Enjoyment of all Economic, Social and Cultural Rights (Art. 3) 69–70
- Convention on Biological Diversity (CBD) 73, 73(*n*50), 74(*n*54), 74–7, 94–5(*n*60) 108, 129
- Article 8(j) 74(*n*54)
- Article 15 74(*n*53), 75, 76
- Biotechnology Directive 108
- TRIPS and intellectual property rights 73, 73(*n*50), 76–7, 108
- Declaration of Commitment on HIV/AIDS 57–8
- Declaration on the Right to Development 61–2, 63, 63(*n*9), 64, 65
- Article 1.1 61
- Article 1.2 62
- Article 8 62
- Article 8.1 62
- High-level Task Force on the Implementation of the Right to Development 64–6
- Open-ended Working Group on Development 64, 66
- Economic and Social Council 55, 64 (*see also* ICESCR)
- General Assembly
- 55th Session, Resolution 55/2, Millennium Declaration, 18 September 2000 49(*n*31) (*see also* United Nations: Millennium Declaration)
- 56th Session, Annex of the Road map towards the implementation of the United Nations Millennium Declaration, 6 September 2001 50(*n*32), 65(*n*21) (*see also* United Nations: Millennium Declaration)
- 59th Session, Report of the Special Rapporteur of the Commission on Human Rights, on the right of everyone to the enjoyment of the highest attainable standard of physical and mental health, 8 October 2004 50, 50(*n*34)
- 60th Session, Resolution 60/251, Human Rights Council, 3 April 2006 49, 49(*n*29)
- 60th Session, Resolution 60/262, Political Declaration on HIV/AIDS, 15 June 2006 57–8
- 61st Session, Report of the Special Rapporteur of the Commission on Human Rights, on the right of everyone to the enjoyment of the highest attainable standard of physical and mental health, 13 September 2006 51, 51(*n*39)
- UNGASS (UN General Assembly Special Session on HIV/AIDS) 57
- Human Rights Council 49, 49(*n*28), 55, 66, 145(*n*15) (*see also* Commission on Human Rights)
- Resolution 6/29 49
- International Covenant on Economic, Social and Cultural Rights (ICESCR) 45–8, 62, 69–70, 71 (*see also* Committee on Economic, Social and Cultural Rights (CESCR))
- Article 2.1 46
- Article 3 69
- Article 12 45–8, 54(*n*53), 61, 72(*n*44), 144, 172, 173, 174
- Article 12.2(c) 46
- Article 12.2(d) 46
- Article 15, 46(*n*14) 68–9, 71
- Article 15.1(a) 69, 70–71, 173
- Article 15.1(b) 25(*n*22), 46(*n*14), 69, 145, 173
- Article 15.1(c) 71
- state obligations 46–7, 69–70
- International Labour Organization (ILO) 55, 55(*n*59)
- Millennium Declaration 49–50, 50(*n*32), 65(*n*21)
- 55th Session, Resolution 55/2, Millennium Declaration, 18 September 2000 49(*n*31)
- 56th Session, Annex to the Road map towards the implementation of the

- United Nations Millennium Declaration, 6 September 2001 50(n32)
- Millennium Development Goals (*see* United Nations: United Nations Development Programme: Millennium Development Goals)
- Millennium Summit 49–50
- Political Declaration on HIV/AIDS 57–9
- Paragraph 12 58(n70)
- Paragraph 15 58(n71)
- Paragraph 43 58(n72)
- Paragraph 44 58(n73)
- Paragraph 46 58(n74)
- Paragraph 47 58(n76)
- Special Rapporteur on the right to health 47(n23), 49–52, 52(n43)
- Human Rights Guidelines for Pharmaceutical Companies in relation to Access to Medicines 52–3, 66
- United Nations Children's Fund (UNICEF) 55(n59), 179
- United Nations Development Programme (UNDP) 14, 24–5, 55, 55(n59)
- Human Development Report 2000: *Human Rights and Human Development: For Freedom and Solidarity* 25(n23)
- Human Development Report 2003: *Millennium Development Goals: A Compact Among Nations to End Human Poverty* 14(n40),
- Millennium Development Goals (MDG) 14(n40), 49–51, 53, 57–8, 63(n9), 65, 65(n18), 66, 81, MDG 6 50, 53, 58
- MDG 8 65
- MDG Target 17 65–6
- Millennium Development Goals Report, 2008 50(n32), 53(n49), 53(n52)
- UNAIDS/UNDP Red Ribbon Award (*see* United Nations: UNAIDS: UNAIDS/UNDP Red Ribbon Award)
- United Nations Educational, Scientific and Cultural Organization (UNESCO) 55, 55(n59), 103
- Universal Declaration on the Human Genome and Human Rights 1997 103
- Article 1 103(n9)
- United Nations Environment Programme (UNEP) 73
- United Nations High Commissioner for Refugees (UNHCR) 55(n59)
- United Nations Joint Programme on HIV/AIDS (UNAIDS) 49, 55, 59, 59(n80), 156, 156(n50), 157(n54), 189
- High Level Meeting on AIDS 57–9
- OHCHR/UNAIDS, *International Guidelines on HIV/AIDS and Human Rights* 55, 55(n60), 56, 56(n61), 57, 57(n64), 145, 145(n14)
- UNAIDS, *AIDS Epidemic Update Regional Summaries* 156–7
- UNAIDS, *Intensifying HIV Prevention* 59(n80)
- UNAIDS/UNDP Red Ribbon Award 54(n53)
- United Nations Office of the High Commissioner for Human Rights (OHCHR) 45, 50, 55
- United Nations Office on Drugs and Crime (UNODC) 55(n59)
- United Nations Population Fund (UNPFA) 55(n59)
- Universal Declaration on Human Rights (UDHR) 44, 106
- UDHR Article 3 106, 106(n16)
- UDHR, Article 25(1) 44, 44(n11)
- UDHR, Article 4 106
- Vienna Declaration and Programme of Action 63–4, 63(n9)
- World Conference on Human Rights 63–4, 63(n9)
- World Food Programme (WFP) 55(n59)
- World Health Organization (WHO) (*see* World Health Organization (WHO))

- World Intellectual Property Organization (WIPO) (*see* World Intellectual Property Organization (WIPO))
- United States
- abbreviated new drug applications (ANDA) 180
 - Act of 1790, An Act to promote the progress of useful arts 19(*n1*)
 - Act of 1793, An Act to promote the progress of useful arts, and to repeal the Act heretofore made for that purpose 19(*n1*)
 - Act of 1800, An Act to extend the privilege of obtaining patents for useful discoveries and inventions, to certain persons therein mentioned, and to enlarge and define the penalties for violating the rights of patentees 19(*n2*)
 - Act of 1832, An Act concerning the issuing of patents to aliens, for useful discoveries and inventions 19(*n2*)
 - Act of 1836, An Act to promote the progress of useful arts, and to repeal all Acts and parts of Acts heretofore made for that purpose 19(*n2*)
 - Bayh-Dole Act (University and Small Business Patent Procedures Act) 180, 180(*n28*)
 - Center for Disease Control (CDC) 169
 - Food and Drug Administration (FDA) 89, 89 (*n42*), 90, 118, 159, 180, 181, 181(*n33*), 184
 - Food, Drug and Cosmetic Act, 21 U.S.C. 355 89, 180, 181, 181(*n36*)
 - Hatch-Waxman Act (Drug Price Competition and Patent Term Restoration Act) 180–81
 - Medical Innovation Prize Fund Bill (Sanders Bill) 191 (*see also* prizes)
 - National Institutes of Health (NIH) 128, 129, 134(*n53*), 158, 169, 180
 - Orphan Drug Act 181
 - Prescription Drug User Act (PDUFA) 118(*n63*)
 - Special 301 Watch List 157
 - United States Trade Representative (USTR) 157
 - unity 6, 10, 11, 13, 22, 34, 79–80, 81, 103
 - Universal Declaration of Human Rights 1948 (*see* United Nations: Universal Declaration of Human Rights (UDHR))
 - Universities Allied for Essential Medicines (UAEM) 189
 - UNODC (*see* United Nations: United Nations Office on Drugs and Crime (UNODC))
 - UNPFA (*see* United Nations: United Nations Population Fund (UNPFA))
 - use (*see also* access)
 - access and use 22, 25, 28, 80, 125, 146, concept and definition of 1–2, 37–8, 174, 190
 - cultural nature and value of 25–6, 37, 38, 77, 101, 144–5
 - gene-related inventions 26–8
 - invention and scope 22, 26, 27, 28, 32–5, 37–8, 77, 113
 - ownership and possession 2, 125, 145–6, 173, 174
 - participation and identity 62, 97, 143, 144, 172, 173, 189, 192, 193
 - use-value 22, 109–10
 - user 2, 6, 7–9, 11, 19, 22–3, 34, 36, 37–8, 77, 93, 104–5(*n13*), 121, 137, 143–4, 148, 169, 189–90, 192, 193
 - USTR (*see* United States: United States Trade Representative (USTR))
 - utilitarianism 23, 24, 110
 - vaccines 67, 74, 128–9, 135, 163–5, 167, 168, 168(*n100*), 169, 179, 181–2, 190–91
 - value-based pricing (*see* pricing)
 - vassals 173
 - Vienna Declaration and Programme of Action (*see* United Nations: Vienna Declaration and Programme of Action)
 - viruses 74, 128 (*see also* avian influenza; influenza)
 - genetic resources 74, 163–9

- sampling 128–9
 sharing and donation 74, 74(n52), 126,
 137(n66), 163–9
 Voltaire 193
- Weber, Max 5(n2), 8–9, 8(n13), 8(n14),
 9(n15), 13(n35), 16, 23, 26(n27),
 79(n3), 80(n5), 81(n8), 84(n18)
- Wellcome Trust 132(n41), 134(n53), 135
- WFP (*see* United Nations: World Food
 Programme (WFP))
- WHO (*see* World Health Organisation
 (WHO))
- will and will-formation 1
 commercial 2, 143, 147, 187
 political 41(n1), 42, 45, 147, 163
 property 79
- WIPO (*see* World Intellectual Property
 Organization (WIPO))
- World Bank 55(n59), 156
- World Conference on Human Rights,
 1993 (*see* United Nations: World
 Conference on Human Rights)
- World Food Programme (WFP) (*see*
 United Nations: World Food
 Programme (WFP))
- World Health Assembly (*see* World
 Health Organization (WHO): World
 Health Assembly (WHA))
- World Health Organization (WHO) 1,
 8(n12), 9–10, 49, 53, 55, 58–9, 66, 72,
 81, 120, 130, 144, 161, 163, 164, 165,
 181, 185, 189, 190
- Action Programme on Essential Drugs
 47
- Civil Society Initiative (CSI) 130, 144
- Closing the Gap in a Generation: Health
 Equity through Action in the Social
 Determinants of Health* 8(n12),
 10(n20), 15, 15(n41), 15(n43),
 16(n44), 120(n5)
- Collaborating Centres (CC) 163, 168,
 168(n100), 169
- Commission on Social Determinants of
 Health (CSDH) 8(n12), 15, 15(n41)
- Constitution 9–10, 10(n18), 10(n19),
 42–3, 42(n6), 43(n7), 43(n8), 44, 53
- Declaration of Alma-Ata 53–5
- Department of Medicines Policy and
 Standards 51, 51(n42)
- Effective Aid: Better Health* 10(n21),
 130(n29)
- Equitable Access to Essential
 Medicines: A Framework for
 Collective Action* 2004 53(n52)
- Essential Medicines List (EML) 53,
 161, 161(n80), 184–5
- Global Influenza Surveillance Network
 (GISN) 74(n52), 163–4
- Global Strategy and Plan of Action
 on Public Health, Innovation and
 Intellectual Property 10(n23), 53,
 66–8, 67(n27), 190–91
- Guidelines for Drug Donations* 53
- H5 Reference Laboratory Network 164
- health, definition of 9–10, 42–4
- Intergovernmental Working Group
 (IGWG) 66–7, 188, 191
- International Nonproprietary
 Names (INN) 185–7 (*see also*
 International Nonproprietary
 Names (INN))
- Pandemic Influenza Preparedness
 (PIP) 74(n52), 165–9
- Traditional Medicine Strategy
 2002–2005 72
- UNITAID 58–59, 189
- World Health Assembly (WHA)
 10(n22), 42(n6), 67, 184–5
- 3rd Session
 Resolution WHA3.11 185(n51)
- 31st Session
 Resolution WHA31.32 184–5,
 185(n50)
- 59th Session 55, 55(n55), 66, 67(n27)
 Resolution WHA 59.24 66,
 66(n25), 67–8, 67(n27),
 67(n29), 68(n30)
- 60th Session, 190
 Resolution WHA60.28 165,
 165(n90)
- Resolution WHA60.30 190,
 190(n72), 191(n76)
- 61st Session 10, 66
 Resolution WHA 61.21 10(n23),
 66(n26), 67(n27)

- World Intellectual Property Organization (WIPO)
- Committee for Development and Intellectual Property (CDIP) 15(*n42*)
 - Development Agenda 15(*n42*)
 - Intergovernmental Committee on Intellectual Property and Genetic Resources, Traditional Knowledge and Folklore (IGC) 72(*n43*), 73, 73(*n48*)
 - World Patent Report 6(*nn4–5*)
- World Trade Organization (WTO)
- Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) 2, 20, 21, 25, 52, 57, 67–8, 73, 108, 145, 149, 157, 158
 - Article 4 57(*n66*), 82(*n11*), 83
 - Article 6 157(*n59*)
 - Article 8 145, 146(*n16*)
 - Article 27 23(*n19*), 93(*n56*)
 - Article 27.1 26(*mn31–2*), 160, 191(*n75*)
 - Article 27.2 93(*n57*), 95(*mn61–2*), 110(*n31*), 160(*n72*)
 - Article 27.3 160(*n72*)
 - Article 27.3(a) 93(*n56*)
 - Article 27.3(b) 108(*n26*)
 - Article 28 27(*n39*), 124(*n14*), 192
 - Article 29 93(*n56*)
 - Article 29.1 27(*n35*)
 - Article 29*bis*.1 76, 76(*n59*)
 - Article 29*bis*.2 76(*n60*)
 - Article 30 93(*n56*), 192
 - Article 31 146(*n17*), 147, 148, 152
 - Article 31(b) 148(*n23*)
 - Article 31(f) 148(*n24*), 151, 152, 154
 - Article 31*bis* 151, 151–2, 153–4
 - Article 31*bis* 154(*n41*)
 - Article 33 27(*n37*)
 - Article 39 122(*n9*)
 - Article 65.1 21(*n12*)
 - Article 65.2 21(*n12*)
 - Article 65.4 21(*n13*)
 - Biotechnology Directive 108
 - CBD 73, 73(*n50*), 76–7
 - Council for Trade-Related Aspects of Intellectual Property Rights (TRIPS Council) 73(*n50*), 76, 150, 151(*n34*), 152, 153, 154(*n42*)
 - flexibilities 52, 57, 58, 67–8, 108, 147–50, 161, 161(*n75*), 162–3
 - India and compliance 159–61
 - prizes 191–2
 - public health 58, 67–8, 145–8, 149–51
 - public health amendment 2, 146, 151–5
 - transitional periods 21, 149, 154
 - Decision on Paragraph 6 52, 151–2, 151(*n32*), 151(*n34*), 152, 152(*n36*), 154–5, 154(*n42*), 155(*n45*)
 - Doha Declaration on TRIPS and Public Health 21(*n13*), 52, 149–51, 151(*n34*)
 - Paragraph 4 149, 149(*n28*), 150
 - Paragraph 5 149, 149(*n29*)
 - Paragraph 6 150, 151(*n34*)
 - Paragraph 8 151(*n34*)
 - Doha Development Agenda 149
 - Doha Ministerial Declaration 2001 67–8, 73(*n50*), 149
 - Paragraph 6 System, 150–55
 - Rwanda-Canada notification 151(*n34*), 154–5, 155(*n45*)
 - WTO Panel, ‘Canada: Patent Protection of Pharmaceutical Products’ 192, 192(*n80*)
- WTO (*see* World Trade Organization (WTO))
- Wyeth 183
- Zidovudine 155